ADVANCED BIOANALYSIS
Advanced bioanalytical technologies for systems biology studies
| Coordinatore | ARISTOTELIO PANEPISTIMIO THESSALONIKIS
Organization address
address: Administration Building, University Campus contact info |
| Nazionalità Coordinatore | Greece [EL] |
| Totale costo | 45˙000 € |
| EC contributo | 45˙000 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2007-2-2-ERG |
| Funding Scheme | MC-ERG |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-01-01 - 2011-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ARISTOTELIO PANEPISTIMIO THESSALONIKIS
Organization address
address: Administration Building, University Campus contact info |
EL (THESSALONIKI) | coordinator | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The current reintegration grant (ERG) will facilitate the initiation of systems biology/ metabonomics research at the Aristotle University. This would capitalise on the training, the links and the experience obtained by Dr. Helen Gika during her post-doctoral study in AstraZeneca UK (AZ) through the Transfer of Knowledge “Biomarker Discovery” (TOK-Industry Academia Partnership 29640). Dr. Gika is the main researcher of the TOK-IAP grant. It is now very important to continue on the generated knowledge and further build on the established links and co-operations. The ERG will last for three years. The project is strongly endorsed by both the Aristotle University (AUTh) and AZ. AZ will be actively involved providing financial, scientific and material support and access to facilities. AUTh will provide the base for Dr Gika to set up her research team. The AUTh researchers trained in the TOK grant will be central to the new ERG project, facilitating transfer of knowledge and continuing the research. The research focus retains a biopharmaceutical perspective in an upcoming field with major investments from pharmaceutical companies. The ERG work will aim towards the development of advanced metabolomic analytical tools, with emphasis on the utilisation of LC-MS technologies and the subsequent treatment of data with advanced data processing software. The major goal/scope of the studies will be in the area of disease biomarker discovery, drug efficacy, toxicology and safety assessment benefiting from the links and the close cooperation with groups in AZ. Together with the development of the project and the establishment of the group in AUTh, in order to maximise integration in the national research area, emphasis will be placed on “ethnopharmacological” issues and specific disease states common to the population of Greece or the Eastern Mediterranean: such as e.g. Mediterranean anaemia. This is expected to maximize the future involvement of local biomedical experts.'